Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15214489 | 0.87 | TLR2 (0.47) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL10045807 | 0.85 | HDAC1 (0.41) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL12938696 | 0.76 | KMT2A (0.51) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL21848145 | 0.76 | KMT2A (0.51) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL6795717 | 0.74 | KMT2A (0.54) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL732417 | 0.73 | KMT2A (0.53) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL8453044 | 0.73 | KMT2A (0.56) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL1343999 | 0.73 | KMT2A (0.53) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL4287694 | 0.73 | KMT2A (0.53) | CASP3EPHX2KMT2AMDM4TP53 | |
| SCHEMBL28946743 | 0.73 | CASP3 (0.49) | CASP3EPHX2KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | CASP3 599/4885EPHX2 4072/4885KMT2A 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.